{"id":"hydrocortisone-placebo-and-propranolol","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Infection risk (from immunosuppression)"}]},"_chembl":{"chemblId":"CHEMBL1671","moleculeType":"Small molecule","molecularWeight":"295.81"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydrocortisone reduces inflammation and immune activation by binding glucocorticoid receptors, while propranolol blocks beta-adrenergic signaling to reduce heart rate and blood pressure. The placebo arm allows for controlled assessment of the active agents' contribution to clinical outcomes in the studied condition.","oneSentence":"This combination uses hydrocortisone (a glucocorticoid) and propranolol (a beta-blocker) to suppress inflammatory and adrenergic responses, with placebo control to assess efficacy.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:40:11.109Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction or acute coronary syndrome (investigational combination)"}]},"trialDetails":[{"nctId":"NCT06982183","phase":"PHASE4","title":"The Effects of Propranolol, Hydrocortisone, and Morphine on Military-Relevant Performance Outcomes","status":"RECRUITING","sponsor":"Walter Reed Army Institute of Research (WRAIR)","startDate":"2025-05-27","conditions":"Fear of Spiders, Acute Stress Reaction","enrollment":110},{"nctId":"NCT01070225","phase":"PHASE4","title":"Reversal of Acute β-Blocker Induced Bronchoconstriction","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2010-03","conditions":"Asthma","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hydrocortisone/ Placebo and Propranolol","genericName":"Hydrocortisone/ Placebo and Propranolol","companyName":"University of Dundee","companyId":"university-of-dundee","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses hydrocortisone (a glucocorticoid) and propranolol (a beta-blocker) to suppress inflammatory and adrenergic responses, with placebo control to assess efficacy. Used for Acute myocardial infarction or acute coronary syndrome (investigational combination).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}